264608-41-5

Basic information

• Product Name: 1-pyridin-2-ylpiperidin-4-one
• Synonyms: 1-pyridin-2-ylpiperidin-4-one;4-Piperidinone, 1-(2-pyridinyl)-
• CAS NO: 264608-41-5
• Molecular Formula: C₁₀H₁₂N₂O
• Molecular Weight: 176.21508
• Mol File: 264608-41-5.mol

Chemical Properties

• Boiling Point: 340.8±32.0 °C(Predicted)
• Appearance: /
• Density: 1.163±0.06 g/cm3(Predicted)
• Storage Temp.: 4°C, Inert atmosphere
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• PKA: 8.11±0.19(Predicted)
• CAS DataBase Reference: 1-pyridin-2-ylpiperidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-pyridin-2-ylpiperidin-4-one(264608-41-5)
• EPA Substance Registry System: 1-pyridin-2-ylpiperidin-4-one(264608-41-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 264608-41-5(Hazardous Substances Data)

Usage

Chemical structure

Contains a pyridine ring and a piperidone derivative

Usage

Building block in organic synthesis

Application in pharmaceutical industry

Key intermediate in the synthesis of various drugs and bioactive compounds

Potential pharmacological activities

Antipsychotic and anti-inflammatory agent

Role in coordination chemistry

Ligand

Use as a catalyst

In organic reactions

Versatility

Research and industry applications due to unique chemical structure and properties

Upstream product

• 109-04-6 2-bromo-pyridine 
• 109-09-1 2-chloropyridine 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 264608-40-4 8-(pyridin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane 

Downstream Products

• 199117-78-7 N-(2-pyridinyl)-4-hydroxypiperidine 

Relevant articles and documents

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.

Synthesis and Minisci reactions of organotrifluoroborato building blocks

Copper-catalyzed borylation of a variety of organic halides with bis(pinacolato)diboron allows the preparation of diverse potassium organotrifluoroborates. The reactions are mild and general, providing access to a variety of interesting, boron-containing

Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists

A series of 1,2,3,6-tetrahydropyridyl-4-carboxamides, exemplified by 6, have been synthesized and evaluated for in vitro TRPV1 antagonist activity, and in vivo analgesic activity in animal pain models. The tetrahydropyridine 6 is a novel TRPV1 receptor an

OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

Adenosine A2A receptor agonists as antiinflammatory agents

The present invention provides compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, together with processes for the preparation of, compositions containing, uses of and intermediates used in the preparation of such compounds that have A2a receptor agonist activity.